Respiratory drug discovery and development company Synairgen has received expedited approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 in COVID-19 patients to potentially assist with the global outbreak of the virus. SNG001 is an inhaled formulation of interferon-beta-1a.
Came across this really nice write up about the investment case for Synairgen. They’ve just entered their 3rd stage of clinical trials so some nice news could be on the horizon for their COVID treatment.